Importance of patient selection when determining the significance of the CYP3A5 polymorphism in clinical trials

Pharmacogenomics J. 2004;4(6):362-4. doi: 10.1038/sj.tpj.6500286.
No abstract available

Publication types

  • Review

MeSH terms

  • Clinical Trials as Topic / methods*
  • Cytochrome P-450 CYP3A
  • Cytochrome P-450 Enzyme System / genetics*
  • Humans
  • Patient Selection*
  • Polymorphism, Genetic / genetics*

Substances

  • Cytochrome P-450 Enzyme System
  • CYP3A protein, human
  • CYP3A5 protein, human
  • Cytochrome P-450 CYP3A